These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37318556)

  • 21. Statins for children with familial hypercholesterolemia.
    Vuorio A; Kuoppala J; Kovanen PT; Humphries SE; Tonstad S; Wiegman A; Drogari E; Ramaswami U
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SAMSON and the Nocebo Effect: Management of Statin Intolerance.
    Krishnamurthy A; Bradley C; Ascunce R; Kim SM
    Curr Cardiol Rep; 2022 Sep; 24(9):1101-1108. PubMed ID: 35759168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
    JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?
    Jacobson TA
    Mayo Clin Proc; 2006 Sep; 81(9):1225-31. PubMed ID: 16970219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adding ezetimibe to statin therapy: latest evidence and clinical implications.
    Vavlukis M; Vavlukis A
    Drugs Context; 2018; 7():212534. PubMed ID: 30023003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects.
    Li JJ; Liu HH; Wu NQ; Yeo KK; Tan K; Ako J; Krittayaphong R; Tan RS; Aylward PE; Baek SH; Dalal J; Fong AYY; Li YH; O'Brien RC; Lim TSE; Koh SYN; Scherer DJ; Tada H; Kang V; Butters J; Nicholls SJ
    Expert Opin Drug Metab Toxicol; 2020 Sep; 16(9):837-851. PubMed ID: 32729743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature.
    Yu M; Liang C; Kong Q; Wang Y; Li M
    Lipids Health Dis; 2020 Jan; 19(1):1. PubMed ID: 31900179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of the patient with statin intolerance.
    Vandenberg BF; Robinson J
    Curr Atheroscler Rep; 2010 Jan; 12(1):48-57. PubMed ID: 20425271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE; Davidson M; Jones MR; Abby SL
    Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies to overcome statin intolerance.
    Agouridis AP; Nair DR; Mikhailidis DP
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):851-5. PubMed ID: 25786568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
    Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B
    JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
    Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
    Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.
    Schreml J; Gouni-Berthold I
    Curr Med Chem; 2018; 25(13):1538-1548. PubMed ID: 28618994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statins for children with familial hypercholesterolemia.
    Vuorio A; Kuoppala J; Kovanen PT; Humphries SE; Tonstad S; Wiegman A; Drogari E
    Cochrane Database Syst Rev; 2014 Jul; (7):CD006401. PubMed ID: 25054950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study--the Ezetrol Add-On Study.
    Bissonnette S; Habib R; Sampalis F; Boukas S; Sampalis JS;
    Can J Cardiol; 2006 Oct; 22(12):1035-44. PubMed ID: 17036098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
    Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
    Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.